软组织肉瘤,免疫检查点抑制剂,PD-1抑制剂,PD-L1抑制剂,CTLA-4抑制剂," /> 软组织肉瘤,免疫检查点抑制剂,PD-1抑制剂,PD-L1抑制剂,CTLA-4抑制剂,"/> Soft tissue sarcomas,Immune checkpoint inhibitors,PD-1 inhibitor,PD-L1 inhibitor,CTLA-4 inhibitor,"/>  <span style="font-family:宋体;">免疫检查点抑制剂在软组织肉瘤中的应用</span><span style="font-family:'Times New Roman','serif';">:</span><span style="font-family:宋体;">现状与展望</span><span style="font-family:'Times New Roman','serif';"></span>

临床肿瘤学杂志 ›› 2023, Vol. 28 ›› Issue (01): 77-83.

• 综述与讲座 • 上一篇    

 免疫检查点抑制剂在软组织肉瘤中的应用:现状与展望

  

  1.  210008  南京  南京大学医学院附属鼓楼医院肿瘤中心暨南京大学临床肿瘤学研究所
  • 收稿日期:2022-05-22 修回日期:2022-11-15 出版日期:2023-01-31 发布日期:2023-03-08
  • 通讯作者: 李茹恬 E-mail:rutianli@nju.edu.cn
  • 基金资助:
    国家自然科学基金项目(81972192);南京鼓楼医院新技术发展基金项目(XJSFZJJ202025);基础研究计划自然科学基金项目(BK20220191

 Current status and prospect of immune checkpoint inhibitors in treatment of advanced soft tissue sarcoma

  1. The Comprehensive Cancer Centre of Nanjing Drum Tower Hospital, The Affiliated Hospital of Nanjing University Medical School, Nanjing 210008
  • Received:2022-05-22 Revised:2022-11-15 Online:2023-01-31 Published:2023-03-08

摘要: 软组织肉瘤是一类少见的起源于间叶组织的除骨或软骨以外的恶性肿瘤,发病率低,但晚期转移患者通常缺乏有效的治疗手段,预后差,死亡率高。近年来,免疫检查点抑制剂(ICIs)在恶性肿瘤免疫治疗领域中取得了重要进展。在许多肿瘤中,ICIs有效改善了患者的预后,但在软组织肉瘤中,虽然有相关应用探索,却尚未获得高级别循证医学证据。本文总结了ICIs在软组织肉瘤临床治疗中的进展,包括ICIs单药及与其他治疗手段的联合使用,探讨了ICIs在未来软组织肉瘤治疗中的研究方向,希望为相关临床工作者提供参考。

关键词:  , 软组织肉瘤')">">软组织肉瘤, 免疫检查点抑制剂, PD-1">PD-1抑制剂')">">抑制剂, PD-L1">PD-L1抑制剂')">">抑制剂, CTLA-4">CTLA-4抑制剂">抑制剂')">">

Abstract:  Soft tissue sarcomas (STS) are a rare group of mesenchymal malignancies except bone or cartilage, with a low incidence rate. Patients with advanced STS have limited treatment options, poor prognosis and high mortality. Recently, immune checkpoint inhibitors (ICIs) have made great breakthroughs in the field of tumor therapy, greatly improving the prognosis of patients with various malignancies. However, efficacy of ICIs in the treatment of STS remains unravelled. This review summarizes the role of the ICIs in various sets of advanced STS treatment and provides future research directions, hoping to serve as a reference for clinicians.

Key words:  , Soft tissue sarcomas">Soft tissue sarcomas')">">, Immune checkpoint inhibitors">Immune checkpoint inhibitors')">">, PD-1 inhibitor">PD-1 inhibitor')">">, PD-L1 inhibitor">PD-L1 inhibitor')">">, CTLA-4 inhibitor')">">CTLA-4 inhibitor

中图分类号: 

  •  
[1] 梁宗英, 赵宝山, 郑竞雄, 侯继申, 孙光蕊. 乙酰基转移酶KAT2ASurvivin蛋白乙酰化在食管癌中的相关性研究[J]. 临床肿瘤学杂志, 2023, 28(01): 16-22.
[2] 邱思冲, 徐禄玉, 李柳宁.  基于SEER数据库恶性脑膜瘤预后列线图的构建与验证[J]. 临床肿瘤学杂志, 2023, 28(01): 30-37.
[3] 占天鹏, 何魏, 张勐, 陶燕, 卢建中, 付生军, 李兰兰, 张静, 刘善辉.  UBE2C基因在肾透明细胞癌中的临床预后价值及分子机制探究[J]. 临床肿瘤学杂志, 2023, 28(01): 49-57.
[4] 刘德龙, 蒋穗斌, 郭东铭. MALAT1靶向调控miR-205与骨肉瘤侵袭的实验研究[J]. 临床肿瘤学杂志, 2018, 23(5): 385-390.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!